Moderna Logo (PRNewsFoto/Moderna Therapeutics)
AstraZeneca (LON:AZN) inadvertently discovered halving the first dose of its COVID-19 vaccine could boost its efficacy.
Researchers at the National Institutes of Health (NIH) and Moderna (NSDQ:MRNA) are examining vaccine data to determine whether they can halve the 100-microgram dose to vaccinate twice as many people.
Some data from Moderna’s clinical trial support that possibility, according to Moncef Slaoui, head of Operation Warp Speed.
Get the full story from our sister site, Drug Discovery & Development.
Tell Us What You Think!